A phase 3 trial evaluating ivosidenib plus azacitidine in adults with previously untreated IDH1-mutated AML showed that it met all endpoints. Positive results from a phase 3 trial evaluating ...
Discover comprehensive details about Ivosidenib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Please provide your email address to receive an email when new articles are posted on . Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated ...
• Ivosidenib comes as a tablet that can be taken by mouth either with or without food. • Ivosidenib tablets should be taken at the same time each day as prescribed by the doctor. • Swallow the ...
ATLANTA — Ivosidenib monotherapy was well tolerated in patients with acute myeloid leukemia and an IDH1 mutation, according to results of a first-in-human phase 1 study presented at the ASH Annual ...
The targeted therapy already has indications in acute myeloid leukemia. If approved, ivsosenib would be the first targeted therapy approved for patients with MDS who have a susceptible IDH1 mutation, ...
The evaluation committee considered evidence submitted by Servier, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...
Credit: Getty Images. Findings showed an objective response rate of 83.3% with 38.9% of patients having a complete response. The Food and Drug Administration (FDA) has granted Priority Review for ...
SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational ...
Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult ...
The evaluation committee considered evidence submitted by Servier Laboratories, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback